Epithelial-mesenchymal transition (EMT) is an essential step for tumor progression, although the mechanisms driving EMT are still not fully understood. In an effort to investigate these mechanisms, we observed that heregulin (HRG)-mediated activation of HER2, or HER2 overexpression, resulted in EMT, which is accompanied with increased expression of a known EMT regulator Slug, but not TWIST or Snail. We then investigated how HER2 induced Slug expression and found, for the first time, that there are four consensus HSF sequence-binding elements (HSEs), the binding sites for heat shock factor-1 (HSF-1), located in the Slug promoter. HSF-1 bound to and transactivated the Slug promoter independent of heat shock, leading to Slug expression in breast cancer cells. Mutation of the putative HSEs ablated Slug transcriptional activation induced by HRG or HSF-1 overexpression. Knockdown of HSF-1 expression by siRNA reduced Slug expression and HRG-induced EMT. The positive association between HSF-1 and Slug was confirmed by immunohistochemical staining of a cohort of 100 invasive breast carcinoma specimens. While investigating how HER2 activated HSF-1 independent of heat shock, we observed that HER2 activation resulted in concurrent phosphorylation of Akt and HSF-1. We then observed, also for the first time, that Akt directly interacted with HSF-1 and phosphorylated HSF-1 at S326. Inhibition of Akt using siRNA, dominant-negative Akt mutant, or small molecule inhibitors prevented HRG-induced HSF-1 activation and Slug expression. Conversely, constitutively active Akt induced HSF-1 phosphorylation and Slug expression. HSF-1 knockdown reduced the ability of Akt to induce Slug expression, indicating an essential role that HSF-1 plays in Akt-induced Slug upregulation. Altogether, our study uncovered the existence of a novel Akt-HSF-1 signaling axis that leads to Slug upregulation and EMT, and potentially contributes to progression of HER2-positive breast cancer. 1 Both EMT and MET are also important processes in tumor progression and metastasis whereby EMT facilitates the migration of epithelial tumor cells from the primary site to distant locations, whereas MET allows for extravasation and subsequent colonization at the secondary sites.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a cellular process whereby epithelial cells are reprogrammed to mesenchymal cells. Both EMT and the reverse process MET (mesenchymal-epithelial transition) are critically important in multiple stages of development in vertebrates and invertebrates. 1 Both EMT and MET are also important processes in tumor progression and metastasis whereby EMT facilitates the migration of epithelial tumor cells from the primary site to distant locations, whereas MET allows for extravasation and subsequent colonization at the secondary sites. 2 Direct evidence for these models has been established using animal models of different cancer types, including breast cancer. 3, 4 The transcription factor Slug (SNAI2) promotes EMT by binding to the E-cadherin promoter and repressing E-cadherin expression in epithelial cells, 5 which is accompanied by changes in cell morphology indicating EMT. 6 Slug is considered a marker for malignancy. 7 Another member of the SNAI family, Snail (SNAI1), also binds to the E-cadherin promoter and represses E-cadherin expression in epithelial cells, leading to EMT. 8, 9 Additional EMT transcription factors (for example, TWIST1, ZEB1 and ZEB2) can also repress E-cadherin promoter causing dissolution of cell junctions, loss of cell polarity and enhanced cell migration. 10, 11 HER2 is a member of the ErbB family of receptor tyrosine kinases. 12 HER2 is expressed in 15-20% of breast cancers and HER2-positivity is associated with poor clinical prognosis. [13] [14] [15] Overexpression of HER2 results in overactivation of several pathways in cells, including PI3K-Akt and Ras-MAPK among others. HER2 utilizes these pathways to support tumor growth by promoting cell proliferation, cell survival, tumor angiogenesis and metastasis. 16 Overexpression of HER2 has been shown to associate with E-cadherin downregulation. 17, 18 There is also clinical evidence indicating that patients with HER2-positive metastatic breast cancer have circulating tumor cells that have undergone EMT. 19 However, the mechanisms by which HER2 promotes EMT have not been fully elucidated and are likely complex.
To provide new mechanistic insights into the relationship between HER2 and EMT, we undertook the current study using breast cancer as the study model, and our study provided evidence showing that activation of HER2 induces EMT by upregulating Slug expression in the human breast cancer cells we had examined. A search of the human Slug gene promoter revealed the existence of several putative binding sites for the transcription factor, heat shock factor-1 (HSF-1). HSF-1 is classically activated by heat stress leading to the induction of heat shock proteins (HSPs), which are molecular chaperones that permit repair and refolding to damaged proteins. HSF-1 is constitutively expressed in most tissues but activation can be regulated by post-translational modification, specifically phosphorylation at S326 upon heat stress. 20 Active HSF-1 trimerizes allowing the recognition of HSF sequence-binding elements (HSEs) and upregulation of target genes. 21 Activation of HSF-1 is enhanced in several cancer types, which is associated with a poor prognosis. [22] [23] [24] Subsequently, we found, for the first time, that HSF-1 directly binds to the Slug promoter to induce Slug expression independent of heat shock, and that HER2-activated Akt directly phosphorylates HSF-1 at S326 and activates HSF-1 transcriptional activity. Through these observations, we uncovered a novel HER2-Akt-HSF-1 signaling axis that induces Slug expression and promotes EMT in breast cancer cells, thereby shedding new light on the molecular basis by which HER2-overexpressing breast cancer cells undergo EMT and potentially subsequent metastasis.
RESULTS

Heregulin (HRG) induces EMT and Slug expression in HER2-amplified breast cancer cells
We first investigated whether HRG induced EMT of two HER2-amplified breast cancer cell lines, MDA-MB-453 and BT-474. Both cell lines displayed typical epithelial morphology after serum starvation overnight (day 0) and underwent changes to the mesenchymal-like morphology after HRG treatment (Figure 1a ). To determine which of the EMT regulators may be involved in the observed EMT, we determined levels of Slug, Snail and TWIST with HRG stimulation for 0-120 min, and the results (Figure 1b) showed that the Slug transcripts were significantly induced by HRG in both cell lines. This observation was further confirmed at the protein levels using western blotting (WB; Figure 1c ). Consistent with increased expression of Slug, a transcriptional repressor of E-cadherin, 5 E-cadherin expression level was reduced by HRG. In agreement with observed EMT-like morphological changes in Figure 1a , the mesenchymal marker Vimentin was elevated after HRG treatment (Figure 1c) . We further show that levels of Slug and Vimentin were elevated, whereas E-cadherin expression was suppressed after prolonged HRG treatment (Figure 1d) .
Using a luciferase reporter under the control of the human Slug promoter, we found the Slug promoter was significantly activated by HRG in all three breast cancer cell lines with HER2 amplification (Figure 1e ). Altogether, these observations indicate that HRG induces EMT and Slug expression in HER2-amplified breast cancer cells.
HER2 overexpression enhances Slug expression, leading to EMT in breast cancer cells We next asked whether HER2 overexpression induced EMT using MCF-7 (with normal HER2 expression level) and MCF-7/HER2 (MCF-7 cells stably expressing ectopic HER2). As shown by reverse transcription (RT)-PCR in Figure 2a , forced expression of HER2 upregulated Slug expression which led to reduced E-cadherin expression. WB in Figure 2b confirmed the RT-PCR data and HER2 overexpression in MCF-7/HER2 cells. We further show that HER2 overexpression converted the epithelial appearance of MCF-7 cells into the mesenchymal morphology (Figure 2c ). In the presence of HRG, MCF-7 cells (with normal HER2 expression) also underwent EMT-like morphological changes (Figure 2d ). This observation is consistent with the results in Figure 2e showing that HRG induced Slug promoter activity in MCF-7 cells. Figure 2e also shows that HER2 transient transfection induced Slug promoter activation, which is in agreement with the results with MCF-7/ HER2 stable transfectant cells. Conversely, we observed that Lapatinib, a small molecule HER2/EGFR inhibitor reduced Slug expression in HER2-amplified MDA-MB-453 and SK-BR-3 cells (Figure 2f ). Altogether, these results demonstrate that HER2 overexpression enhances Slug expression, leading to EMT in breast cancer cells.
HSF-1 binds to and transactivates the Slug gene promoter, leading to Slug expression in breast cancer cells To investigate the mechanisms by which Slug expression is upregulated by HER2/HRG, we searched the Slug promoter using TFSearch, a web-based search engine for transcription factor binding sites. Our search revealed that there are four putative HSF-1-binding sites, HSEs, within the Slug promoter (Figure 3a) . Of note, HSF-1 proteins form trimers and recognize three repeats of HSEs, nGAAn or nTTCn (Figure 3a) . 21 Using chromatin immunoprecipitation (ChIP) assay, we found that HSF-1 bound to the Slug promoter and this binding was enhanced by HRG ( Figure 3b ). As a positive control, we observed HSF-1 also bound to the Hsp70 promoter, a known HSF-1 target gene. In ChIP assay, immunoglobulin G (IgG) was used as negative controls for IP, whereas chromatin inputs were used as loading controls for PCR. Using the luciferase reporter assay and WB, we found that HSF-1 expression significantly induced Slug promoter activity ( Figure 3c ) and expression (Figure 3d ), respectively.
To determine whether the putative HSEs are essential for HSF-1-mediated Slug expression, we created two mutant promoters, each with mutations at two of the four putative sites, in order to destroy the three tandem repeats required for binding to HSF-1 trimers (Figure 3a) . The analysis of the wild-type and mutant Slug promoter reporters showed that both mutant reporters lost the ability to respond to HRG induction, indicating the identified HSEs are important for HRG induction of Slug promoter activation (Figure 3e ). Both mutant reporters also lost substantial responsiveness to HSF-1 (Figure 3f ). Finally, we showed that levels of p-HSF-1 (S326) were directly associated with those of Slug in invasive breast carcinoma specimens (Figure 3g ; N ¼ 100, R ¼ 0.56, Po0.000001). In summary, results in Figure 3 indicate that HSF-1 transcriptionally upregulates Slug gene expression in breast cancer cells.
HSF-1 knockdown prevents HRG-induced EMT and suppresses growth of breast cancer cells To complement the HSF-1 upregulation results, we knocked down HSF-1 expression using siRNA to determine its impact on Slug expression and EMT. Our results showed that HSF-1 siRNA reduced the expression of Slug in BT-474 cells (Figure 4a ). The reduction was accompanied with increased expression of E-cadherin and decreased expression of Vimentin. HSF-1 expression was effectively downregulated by HSF-1 siRNA. Moreover, HSF-1 knockdown partially prevented HRG-induced EMT of BT-474 cells, as indicated by the presence of both clustered epithelial-like cells and spindle-shaped mesenchymal-like cells (Figure 4b ). Using the soft agar colony formation assay, we further found that HSF-1 siRNA reduced the propensity of BT-474 cells to grow in an anchorage-independent manner (Figure 4c ).
To further examine whether HSF-1 knockdown will promote MET of mesenchymal post-EMT breast cancer cells, we used MDA-MB-231 cells, a mesenchymal breast cancer cell line. The results showed that HSF-1 siRNA reduced Slug expression, which was accompanied with increased E-cadherin expression and decreased Vimentin levels (Figure 4d ). HSF-1 expression was effectively transcriptional activity. 20 As shown in Figure 5a , HSF-1 phosphorylation status is in concordance with Akt phosphorylation, but not with the other kinases we examined. As expected, Slug expression was enhanced by HRG in both the cell lines.
To confirm the results with concurrent activation of HSF-1 and Akt, we treated the two cell lines with HRG for 0-240 min and determined levels of p-HSF-1 (S326) and p-Akt (S473). The results showed that the kinetics for HSF-1 activation is in concordance with that for Akt (Figure 5b ). Using MCF-7 and MCF-7/HER2 cell lines, we further observed that ectopic HER2 expression led to increased activation of both HSF-1 and Akt in the cells (Figure 5c ). Results in Figure 5 indicate, for the first time, that HSF-1 and Akt are concurrently activated by HRG/HER2 in breast cancer cells.
Akt directly interacts with and phosphorylates HSF-1 at S326
In light of the observation with concurrent activation of Akt and HSF-1, we asked whether these two proteins physically associated. Using IP followed by WB, we found that Akt constitutively interacted with HSF-1 independent of HRG treatment (Figure 6a ). Recombinant Akt directly interacted with recombinant HSF-1 ( Figure 6b ). Next, we investigated whether the Akt-HSF-1 interaction resulted in HSF-1 phosphorylation. Using the cell-free Akt kinase assay followed by WB, we showed that recombinant Akt directly phosphorylated recombinant GST-HSF-1 protein at S326 (Figure 6c ). The same assay further showed that GST-HSF-1 protein was phosphorylated by Akt in time-and dose-dependent manners (Figures 6d-f) . We further investigated whether HSF-1 immunoprecipitated from MCF-7 cells was phosphorylated by recombinant Akt, and the results indicated that cellular HSF-1 was directly phosphorylated by Akt at S326 (Figure 6g ). In agreement with these Figure 7a) , which is consistent with our earlier observation that Akt phosphorylates HSF-1. As positive controls for HSF-1 activity, we found that expression of Hsp70, a known HSF-1 target gene, was reduced in cells with lower levels of p-HSF-1 (Figure 7a ). Using Slug promoter luciferase reporter assay, we further found that both LY294002 and Lapatinib blocked HRG induction of Slug promoter activity (Figure 7c a novel HER2-Akt-HSF-1 signaling axis positively regulates expression of the EMT-promoting transcription factor Slug, and that HSF-1 plays an essential role in Akt-induced Slug expression.
DISCUSSION
Slug participates in several physiological and pathological processes from development to re-epithelialization during wound healing, and to EMT and tumor progression. 7 However, the regulation of Slug expression is still not well understood. In this study, we provide evidence uncovering a novel HER2-Akt-HSF-1 signaling axis that acts to promote Slug expression and EMT whereby HSF-1 directly binds to the Slug promoter to induce transcription.
Our results indicate HSF-1 directly upregulates Slug transcription to promote EMT. This novel observation is in agreement with a recent study suggesting an association between HSF-1 and Slug expression as HER2 þ HSF-1 þ / þ mice showed greater Slug expression in mammary tumors than HER2 þ HSF-1 þ / À mice, which was also accompanied with reduced E-cadherin. 25 We further confirmed this in vitro observation in vivo as we found a strong correlation between active HSF-1 and Slug expression in a sample of 100 invasive breast carcinoma specimens. These experimental findings led us to propose a model whereby overexpression of HER2 activates the PI3K-Akt pathway, which leads to HSF-1 activation/phosphorylation that upregulates Slug expression and promotes EMT of breast cancer cells.
Our results demonstrated that HER2-induced Akt activation leads to Akt phosphorylation of HSF-1 at S326, which results in enhanced HSF-1 transcriptional activity. Interestingly, HRG has been shown to upregulate expression of HSF-1, 26 although the underlying mechanisms are still unclear. It has also been observed that activation of HER2 can upregulate HSF-1 expression whereas loss of HSF-1 reduces HER2-driven tumorigenesis. 26, 27 On the basis of these observations, the relationship between HER2 and HSF-1 appears to be complex warranting further investigations.
Our discovery of HSF-1 being a target of Akt is an important finding. Akt is frequently dysregulated in human cancers and is consequently an important target for cancer therapeutics. Although Akt-targeted therapy has shown promising clinical results, identification of new Akt downstream effectors will help us develop new biomarkers for the aberrant Akt pathway and potentially, novel drug targets for tumors with hyperactive Akt signaling. In light of these notions, the HSF-1 pathway could serve as a new biomarker and a novel therapeutic target for human cancers with high Akt activity, such as, those with PTEN loss, constitutively activated PI3K, or with overexpression of receptor tyrosine kinases, HER2 and EGFR.
In addition to Akt, several other Ser/Thr kinases have been shown to phosphorylate HSF-1 to regulate HSF-1 transcriptional activity, stability and intracellular trafficking. 28 Phosphorylation of HSF-1 at S326 was reported to be a key step in the ability of HSF-1 to regulate gene expression in response to heat stress. 20 However, to date, little evidence has been provided as to what kinases mediate phosphorylation at S326. In this study, we provide conclusive evidence demonstrating that Akt can directly phosphorylate HSF-1 on S326. Interestingly, it was recently reported that mTOR could phosphorylate HSF-1 on S326 in HeLa cells under proteotoxic stress. 29 However, it is worth noting that we did not observe detectable activation of mTOR in the context of HER2 activation in the breast cancer cells we examined. Although Akt has been shown to activate mTOR, 30 we did not observe substantial involvement of mTOR in the Akt-HSF-1-Slug-mediated promotion of EMT in the HER2-amplified breast cancer cells that we have examined. These differences could be explained by several potential mechanisms. First, mTOR-induced phosphorylation of HSF-1 may require mTOR activation from increased cell stress via heat stress or exposure to noxious substances as was observed in a previous study. 29 Second, Akt may act as the predominant regulator of HSF-1 over mTOR in cancer cells with HER2 amplification, as suggested by the data presented in this study. Third, the choice of Akt or mTOR for HSF-1 S326 phosphorylation may differ in a cancer-and/or cell-type dependent manner. Finally, it is likely that HSF-1 S326 residue can be targeted by other Ser/Thr kinases besides Akt and mTOR, which may influence the accessibility of HSF-1 by Akt and/or mTOR.
Our results showed the transcriptional activity of HSF-1 can be activated by the HER2-Akt signaling axis independent of heat shock. This is in agreement with emerging evidence suggesting that HSF-1 can induce a transcriptional program independent of the heat shock program. 23 Importantly, our results further linked HSF-1 to EMT, independent of heat shock, which is clearly a novel, important observation. This observation plus previous reports showing that HSF-1 promotes cell cycle progression and antagonizes apoptosis, 23 together, could help define HSF-1 as a mediator of aggressive tumor phenotypes. These observations also raise the possibility that HSF-1 may have wide-ranging oncogenic functions, thus warranting future in-depth investigations. In support of this possibility, our data suggest that HSF-1 may support HER2-mediated breast cancer cell growth (Figures 4c and f) . This interesting observation is in accordance with several earlier studies. 25, 27, 31 We speculate that the effects of HSF-1 on tumor growth and progression are likely due to a combination of the effects of HSF-1 on the induction of the heat shock program, 22 the induction of genes unrelated to heat shock that support malignant growth 23 and the promotion of EMT as indicated by our results, all three of which can support cell survival and resistance to therapy.
In summary, our study uncovered a novel role for HSF-1 in promoting EMT via direct upregulation of Slug in HER2-amplified breast cancer cells independent of heat shock. Our data also revealed, for the first time, that Akt can directly phosphorylate and activate HSF-1 to induce the expression of Slug. Understanding other post-translational modifications of HSF-1, along with which proteins mediate those modifications, and what role they have in tumor progression, will further elucidate the role that HSF-1 plays in the progression of cancer. It is becoming increasingly apparent that HSF-1 can regulate a vast array of genes outside of the heat shock program. Identification and functional investigations into these HSF-1-targeted genes and cellular mechanisms are certainly warranted to fully understand the role of HSF-1 in cancer. Investigation into the impact of inhibiting HSF-1 is also needed. There are several compounds that have been developed and observed to inhibit HSF-1, including, KRIBB11, 32 KNK437 33 and triptolide. 34 However, the potential therapeutic impact of these compounds in HER2-positive breast cancer models is largely unknown. Thus, there is much left to understand regarding the role of HSF-1 in cancer as evidence continues to suggest that HSF-1 has a much broader biological function than mediating the cellular heat shock response.
MATERIALS AND METHODS
Reagents, cell lines and primary specimens
All chemicals were purchased from Sigma (St Louis, MO, USA) unless otherwise stated. All human breast cancer cell lines used in this study were obtained from ATCC (Manassas, VA, USA), and maintained according to ATCC's instructions. Tissue microarray slides (BC081116) were purchased from US Biomax (Rockville, MD, USA) that contained 100 invasive breast carcinomas. MCF-7/HER2 stable transfectant cell line was a generous gift from Dr Mien-Chie Hung at MD Anderson Cancer Center and was maintained in MEM medium supplemented with 10% FBS, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 10 mg/ml bovine insulin and 350 mg/ml G418. All siRNAs were ordered from Bioneer (Alameda, CA, USA). Western Blotting (WB) and immunoprecipitation (IP) Plasmids, transfection and luciferase assay CA-Akt and DN-Akt constructs were generous gifts from Dr Mong-Hong Lee at MD Anderson Cancer Center. 37 The FLAG-HSF-1 plasmid was purchased from Addgene (ID 32537, Cambridge MA, USA), which was originally established by Dr Stuart Calderwood. 38 Slug_pGL2 luciferase reporter construct was obtained from Addgene (ID 31695), originally cloned by Dr Paul Wade.
39 HER2-WT plasmid was obtained from Addgene (ID 16257), which was generated by Dr Mien-Chie Hung. 40 All transfections were performed with cells in exponential growth using lipofectamine 2000 (Invitrogen) or XtremeGene HP (Roche, Indianapolis, IN, USA). A Renilla luciferase expression vector, pRL-CMV was used to control for transfection efficiency. 48 hr after transfection, the cells were lysed and luciferase activity was measured using the Firefly and Renilla Luciferase Assay Kit (Biotium, Hayward, CA, USA), as we previously described. 10, 35, 36, 41 Relative promoter activity was computed by normalizing the Firefly luciferase activity against that of the Renilla luciferase.
Mutagenesis
Generation of mutant Slug promoter reporter vectors was carried out using a QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer's instructions. Primers used for mutagenesis were: ChIP Assay to determine binding of HSF-1 to the Slug gene promoter This was performed using a ChIP Assay Kit (Upstate, Billerica, MA, USA) as we described previously. 41 Rabbit polyclonal HSF-1 antibody was used (4356, Cell Signaling). DNA sequences for the primers used to amplify the Slug promoter are 5 0 -TGGAAGTGGCATCTGGAGAG-3 0 (forward) and 5 0 -GC TAACACGGTGACATGAGT-3 0 (reverse), and for the Hsp70 promoter, 5 0 -CA CTCCCCCTTCCTCTCAG-3 0 (forward) and 5 0 -TTCCCTTCTGAGCCAATCAC-3 0 (reverse).
Immunohistochemistry (IHC)
This was conducted as we described previously. 42 The slides were incubated with p-HSF-1 (S326) (Abcam) and Slug (Abgent) antibodies. Histologic scores (H-Scores) were computed from both percent positivity (A%, A ¼ 1-100) and intensity (B ¼ 0-3) using the equation, H-Score ¼ A x B.
Determination of anchorage-independent growth by colony formation assays Clonogenic growth assays were performed in six-well cell culture plates with 2000 cells per well, as we previously described. 41, 43 All wells were precoated with 0.5% agarose at the bottom layer whereas the top layer is consisted of 0.3% agarose and tumor cells. After 6-8 weeks, colonies were stained with crystal violet blue solution (Sigma) for 1 h and counted under a microscope. Triplicate wells were used for each cell line and three independent experiments were performed.
Akt kinase assay
Recombinant AKT and recombinant HSF-1 were purchased from Sigma. Indicated amounts of recombinant GST-HSF-1 (0.1-0.4 mg) was incubated with or without 0.1 mg recombinant AKT for up to 60 min at 37 1C in the presence of ATP in kinase assay buffer (20 mM HEPES, 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT). Samples were then boiled and subjected to SDS-PAGE and WB with indicated antibodies.
Statistical analysis
Student's t-test and linear regression analysis were performed using STATISTICA (StatSoft Inc., Tulsa, OK, USA) and Microsoft Excel, as we previously described. 35, 42, 44 
